Cat Allergy – Pipeline Review, H2 2013

Summary

Global Markets Direct’s, ‘Cat Allergy – Pipeline Review, H2 2013’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cat Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cat Allergy. Cat Allergy – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– A snapshot of the global therapeutic scenario for Cat Allergy.

– A review of the Cat Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

– Coverage of products based on various stages of development ranging from discovery till registration stages.

– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

– Coverage of the Cat Allergy pipeline on the basis of route of administration and molecule type.

– Key discontinued pipeline projects.

– Latest news and deals relating to the products.

Reasons to buy

– Identify and understand important and diverse types of therapeutics under development for Cat Allergy.

– Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

– Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

– Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cat Allergy Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for Cat Allergy 7

Cat Allergy Therapeutics under Development by Companies 9

Late Stage Products 10

Comparative Analysis 10

Discovery and Pre-Clinical Stage Products 11

Comparative Analysis 11

Cat Allergy Therapeutics - Products under Development by Companies 12

Companies Involved in Cat Allergy Therapeutics Development 13

ALK-Abello A/S 13

Circassia Holdings Ltd. 14

Biomay AG 15

Cat Allergy - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Drug Profiles 21

Cat-SPIRE - Drug Profile 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

ALK Recombinant Cat Vaccine - Drug Profile 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Cat Allergen Peptide Carrier Fusion Vaccine - Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Cat Allergen Vaccine - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Cat Allergy Therapeutics - Drug Profile Updates 28

Cat Allergy Therapeutics - Discontinued Products 30

Cat Allergy Therapeutics - Dormant Products 31

Cat Allergy - Product Development Milestones 32

Featured News & Press Releases 32

Feb 25, 2013: Circassia's ToleroMune Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start Of Short-course Therapy 32

Oct 04, 2012: Circassia Initiates Pivotal Phase III ToleroMune Trial In Cat Allergen-induced Rhinoconjunctivitis 32

Sep 27, 2012: Circassia Announces Publication Of ToleroMune Cat Allergy Treatment Clinical Results In Journal of Allergy And Clinical Immunology 33

Jun 13, 2011: Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction In Allergy Symptoms During 12-Month Follow-up 34

Feb 01, 2011: Circassia's ToleroMune T-cell Vaccine Achieves Significant Reduction In Allergy Symptoms In Key Phase II Clinical Study 34

Jan 19, 2010: Circassia Extends Its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite And Cat Allergies 35

Nov 20, 2009: Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune Cat Allergy Therapy 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 38

Disclaimer 38



List of Tables

Number of Products Under Development for Cat Allergy, H2 2013 7

Products under Development for Cat Allergy - Comparative Analysis, H2 2013 8

Number of Products under Development by Companies, H2 2013 9

Comparative Analysis by Late Stage Development, H2 2013 10

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11

Products under Development by Companies, H2 2013 12

ALK-Abello A/S, H2 2013 13

Circassia Holdings Ltd., H2 2013 14

Biomay AG, H2 2013 15

Assessment by Monotherapy Products, H2 2013 16

Assessment by Stage and Route of Administration, H2 2013 18

Assessment by Stage and Molecule Type, H2 2013 20

Cat Allergy Therapeutics - Drug Profile Updates 28

Cat Allergy Therapeutics - Discontinued Products 30

Cat Allergy Therapeutics - Dormant Products 31



List of Figures

Number of Products under Development for Cat Allergy, H2 2013 7

Products under Development for Cat Allergy - Comparative Analysis, H2 2013 8

Products under Development by Companies, H2 2013 9

Late Stage Products, H2 2013 10

Discovery and Pre-Clinical Stage Products, H2 2013 11

Assessment by Monotherapy Products, H2 2013 16

Assessment by Route of Administration, H2 2013 17

Assessment by Stage and Route of Administration, H2 2013 18

Assessment by Molecule Type, H2 2013 19

Assessment by Stage and Molecule Type, H2 2013 20